Kay Dickersin: key obituary facts
Is Kay Dickersin dead? Yes. Kay Dickersin died on November 1, 2026, at age 74.
Cause of death: Kay Dickersin's cause of death has not been publicly confirmed.
What was Kay Dickersin known for?
She was an epidemiologist.
More about Kay Dickersin
Born: 10 November 1951.
Place of birth: Philadelphia.
Gender: female.
Occupation: researcher, professor, epidemiologist.
Nationality: United States.
Education: University of California, Berkeley, Johns Hopkins University.
Employer: University of Maryland, Baltimore, Johns Hopkins University.
Occupations: Professor, researcher.
Known for: Research on publication bias, research on selective outcome reporting, strengthening research integrity, Cochrane Collaboration, consumer engagement in research.
Kay Dickersin, an epidemiologist, researcher and professor known for her work on research integrity, died November 1, 2026, aged 74.
Trained first in cell biology and later in epidemiology, she built a career examining how research is conducted and reported, with particular attention to publication bias and selective outcome reporting. Her work also addressed ways to strengthen research integrity and involve consumers in research.
Dickersin earned bachelor’s and master’s degrees in zoology, with a focus on cell biology, from the University of California, Berkeley. At the Johns Hopkins Bloomberg School of Public Health, she served as a professor in the Department of Epidemiology and directed its Center for Clinical Trials and Evidence Synthesis. She also led the US Cochrane Center and the US Satellite of the Cochrane Eyes and Vision Group within the Cochrane Collaboration, organizations focused on the assessment and synthesis of health evidence. Her research brought attention to the effects of which studies are published and which outcomes are reported, issues that can shape the evidence available to researchers and the public. Dickersin retired at the end of 2018 as professor emerita at Johns Hopkins. She received multiple awards for her research. Her career joined epidemiology and clinical-trial methods with efforts to improve transparency in research and support meaningful consumer engagement.
